BOARD OF DIRECTORS
G. Kirk Raab
Chairman of the Board
G. Kirk Raab has served as Chairman of the Board of Protalex since July 2003. A pioneer of the biotechnology industry, Mr. Raab currently sits on the Boards and serves as Chairman of several life science companies, as well as that of The National Foundation for Science and Technology Medals. For 10 years Mr. Raab held leadership positions at Genentech, Inc., one of the first biotech companies founded. In 1985, he joined Genentech as President and Chief Operating Officer and was appointed Chief Executive Officer in 1990; a position he held for five years. Prior to joining Genentech, Mr. Raab was with Abbott Laboratories for 10 years, most recently as President, Chief Operating Officer and Director. Mr. Raab has the distinction of having served as the first Chairman of the Biotechnology Industry Organization and the California Health Care Institute.
Steven H. Kane
President and Chief Executive Officer
Steven H. Kane, President and Chief Executive Officer of Protalex, has served on the Company’s Board of Directors since December 2002 and brings more than 25 years of experience in the healthcare industry to the company. His background encompasses sales, marketing and operations, including successfully raising capital through the public markets. Most recently, Mr. Kane was Vice President of North American Sales and Field Operations for Aspect Medical Systems, where he helped guide that company through a successful initial public offering in January 2000. Prior to that, Mr. Kane was Eastern Area Vice President for Pyxis Corporation, where he was instrumental in positioning the company for its initial public offering in 1992. Pyxis later was acquired by Cardinal Health for $1 billion. Earlier in his career, Mr. Kane worked in sales management with Eli Lilly & Company and Becton, Dickinson & Company.
Eugene A. Bauer, M.D.
Eugene A. Bauer, M.D. has served on the Company’s Board of Directors since February 2005. Dr. Bauer brings corporate, industry and academic experience to Protalex. Dr. Bauer is currently Chief Executive Officer and a board member of Neosil Inc., a privately held biotechnology company. Prior, Dr. Bauer was a Senior Client Partner with Korn/ Ferry International and was a founder of Connetics Corporation, a specialty pharmaceutical company, where he continues to serve as an Emeritus Director. Dr. Bauer was previously affiliated with Stanford University Medical Center, serving as Vice President of the center from 1997 to 2001; Dean of the Stanford University School of Medicine from 1995 through 2001; a. Professor in the department of dermatology since 1988; and was Chief of the Dermatology Service at Stanford University Hospital from 1988 to 1995. For the preceding six years, Dr. Bauer was a professor at Washington University School of Medicine. During his career, Dr. Bauer has served as Chairman of two National Institutes of Health study sections of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and has served on a board of scientific counselors for the National Cancer Institute. Dr. Bauer also serves as a director of both Peplin LTD, an Australian public corporation, and of Echo Healthcare Acquisition Corp, a publicly held SPAC and a non-profit Dermatological Organization. Dr. Bauer holds B.S. and M.D. degrees from Northwestern University.
Frank M. Dougherty
Frank M. Dougherty has served on the Company’s Board of Directors since October 2001 and served as the Company’s Corporate Secretary from June 2002 to December 2002. From January 2004 to April 2005, Mr. Dougherty served as the Corporate Secretary and Treasurer of the Company. Mr. Dougherty is a practicing attorney and founder and owner of Frank M. Dougherty P.C., a law firm in Albuquerque, New Mexico. He has practiced law since 1982, and founded his current law firm in November 2001. Prior to becoming a lawyer, Mr. Dougherty practiced as a CPA in Santa Fe, New Mexico. He has an undergraduate degree in economics from the University of Colorado, a graduate degree in accounting from the University of Arizona and a law degree from Texas Tech University.
Carleton A. Holstrom
Carleton A. Holstrom has served on the Company’s Board of Directors since October 2004. Mr. Holstrom was the Chief Financial Officer of Bear, Stearns & Co. and its successor, the Bear Stearns Companies, Inc. for 10 years starting in 1997, and from 1987 to the present, he has been a Managing Director Emeritus. Mr. Holstrom is on the Board of Directors of Custodial Trust Company of Princeton, New Jersey; and Scientific Learning Corporation, where he also served as its Chief Financial Officer from 1996 to 1997. Since 1979, Mr. Holstrom has been an active member of Rutgers University, serving as Chair on the Board of Governors, as a member of the Board of Trustees (of which he continues as an Emeritus Member) and as Chair of the University’s Board of Overseers, of which he is also an Emeritus Member. From 1994 through 2005, Mr. Holstrom served on the University of Wisconsin at Madison College of Letters and Sciences Board of Overseers. From 1989 through the present, he has been on the University of Wisconsin Foundation Board of Directors and was the Vice Chair of that Foundation from 2000 through 2003.
Dinesh Patel, Ph.D
Dinesh Patel, Ph.D has served on the Company’s Board of Directors since September 2003. He is a Managing Director and Founding Partner of vSpring Capital, an early stage venture capital fund. Dr. Patel is responsible for the creation of several life science companies including Ashni Naturaceuticals, Inc.,which specializes in the research, development and marketing of clinically tested and patent-protected naturaceutical products. In addition to founding the Company, Dr. Patel serves as Ashni’s Chairman, President and Chief Executive Officer. In 1999, Dr. Patel co-founded and was the Chairman of Salus Therapeutics, Inc., which in August 2003 was acquired by Genta, Inc. for $30 million. From 1985 through 1999, Dr. Patel served as Co-founder, Chairman of the Board of Directors, President and Chief Executive Officer of TheraTech, Inc., a pioneer in the development and manufacture of innovative drug delivery products. Under Dr. Patel’s guidance, TheraTech, which went public in 1992, established strategic alliances with major pharmaceutical companies including Eli Lilly, Pfizer, Proctor & Gamble, Roche and SmithKline Beecham. In January 1999, TheraTech was acquired for approximately $350 million by Watson Pharmaceuticals, Inc.. Dr. Patel has been the recipient of numerous awards, including U.S. Small Business Administration’s Business Achiever Award, Scientific and Technology Award (State of Utah) and Entrepreneur of the Year Award (Mountain West Venture Group). Dr. Patel earned his undergraduate degree from India and his doctorate degree from the University of Michigan. Dr. Patel is active in the Indian and local communities, serving on several boards and as an active donor for various charitable causes.
Thomas P. Stagnaro
Thomas P. Stagnaro has served on the Company’s Board of Directors since July 2002. Mr. Stagnaro has spent more than 30 years as an executive in the pharmaceutical industry. He is currently President and Chief Executive Officer of Americas Biotech Distributor (ABD), which he founded in June 2004. Prior to founding ABD, Mr. Stagnaro was President and Chief Executive Officer of Agile Therapeutics, Inc., a private company focused on developing women's healthcare products and was President and Chief Executive Officer of both 3-Dimensional Pharmaceuticals, Inc. and Univax Biologics, Inc.. He began his career with Searle Laboratories. Mr. Stagnaro also serves as a director on the boards of InKine Pharmaceutical Corporation and Life Science Research Organization During his career, Mr. Stagnaro has raised over $200 million for three development stage companies and successfully took Univax Biologics public in 1972. He holds three patents and has published numerous articles.
Peter G. Tombros
Peter G. Tombros has served on the Company’s Board of Directors since November 2005 and has broad experience working with emerging and established biotechnology and pharmaceutical companies. Since 2005, Mr. Tombros has been the Professor and Executive in Residence in the Eberly College of Science BS/MBA Program at Pennsylvania State University. Prior, Mr. Tombros served as Chief Executive Officer of VivoQuest, Inc., a private biopharmaceutical company, from 2001 until its sale to XTL Biopharmaceuticals Ltd. in September 2005. For the prior seven years, Mr. Tombros was President, Chief Executive Officer and Director of Enzon, Inc. During his tenure, Enzon’s market cap grew from $44 million to $3 billion. Mr. Tombros spent the preceding 25 years serving in a variety of senior management positions at Pfizer, Inc., including Vice President of Marketing; Senior Vice President and General Manager of the Roerig Pharmaceuticals Division; Executive Vice President of Pfizer Pharmaceuticals Division; Director, Pfizer Pharmaceuticals Division; Vice President-Corporate Strategic Planning; and Vice President-Corporate Officer of Pfizer, Inc. Mr. Tombros has served as a Director of several life science companies including NPS Pharmaceuticals, Inc., Cambrex Corp. and Dendrite International, Inc. He is currently Chairman of the Board of Alpharma, Inc. Mr. Tombros received B.S. and M.S. degrees from the Pennsylvania State University and an M.B.A. from the University of Pennsylvania , Wharton Graduate School of Business.